



Inventor(s): ENGEL et al
Appln. No.: 08 | 468,145
Series Code ↑ | Serial No. ↑

Filed: June 6, 1995
Title: OLIGOPEPTIDE LYOPHILISATE . . . USE

Asst. Commissioner of Patents
Washington, D.C. 20231

RECEIVED

APR 24 1998

Sir:

REPLY/AMENDMENT/LETTER

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. "Small Entity" statement(s) filed <input type="checkbox"/> previously <input type="checkbox"/> herewith (No.)		Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code
2. Total Effective Claims		20	**minus 20	0	x \$22/\$11 =	+ 0	103/203
3. Independent Claims		4	***minus 3	1	x \$82/\$41 =	+ 82	102/202
4. If amendment enters <u>proper</u> multiple dependent claim(s) into this application for <u>first</u> time (leave blank if this is a reissue application)		add		+ \$270/\$135 =	+ 0		104/204
5. Original due Date: APRIL 22, 1998		<input type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached		(1 mo)	\$110/\$55 =				115/215
		(2 mos)	\$400/\$200 =	+ 0			116/216
		(3 mos)	\$950/\$475 =				117/217
7. Enter any previous extension fee paid since above original due date and subtract				-			
8.				Extension Fee Attached	+ 0		
9. If <u>Terminal Disclaimer</u> attached, add Rule 20(d) official fee				+ \$110/\$55 =	+ 0		148/248
10. If I <u>S</u> attached requires Official Fee,		add	+ \$240 =				126
or if Rule 97(d) Petition		add	+ \$130 =	+ 0			122
11. After-Final Request Fee per rules 129(a) and 17(r)				+ \$790/395 =	+ 0		146/246
12. No. of additional inventions for examination per Rule 129(b)				x \$790/395 ea =	+ 0		149/249
13. Petition fee for					+		
14.				TOTAL FEE ENCLOSED =	\$82		

15. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

16. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

17. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown in the heading hereof, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Madison & Sutro LLP

Intellectual Property Group

By Atty: Ann S. Hobbs, Ph.D. Reg. No. 36,830

1100 New York Avenue, N.W.
Ninth Floor East Tower
Washington, D.C. 20005-3918

04/23/1998 RMBH 0000004 08468145

Atty/Sec: ASH/maf

01 FC:102

Sig: C. S. Hobbs Fax: (202) 822-0944
Tel: (202) 861-3063

82.00 00
NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of

ENGEL et al

Appln. No. 08/468,145

Group Art Unit: 1811

Filed: June 6, 1995

Examiner: N. Minnifield

Title: OLIGOPEPTIDE LYOPHILISATE, THEIR PREPARATION AND USE

* * * * *

April 20, 1998

44
LSD
100
5-2-98

AMENDMENT

Hon. Commissioner of Patents
and Trademarks
Washington, D C. 20231

Sir:

In response to the Office Action issued January 22, 1998,
please enter the following amendments and consider the
following remarks.

IN THE CLAIMS:

Please enter the following claims:

*Sub
LJ
D*
--20. A method for the preparation of a sterile
Cetrorelix lyophilizate, said method comprising the steps of
dissolving Cetrorelix in aqueous acetic acid to form a
solution,
diluting said solution with water for injection,
adding a bulking agent to the solution, and
sterile filtering, dispensing into injection vials and
lyophilizing the solution,
thereby obtaining a sterile Cetrorelix lyophilizate.

RECEIVED

APR 24 1998